Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Oncology Experts Preview Top Abstracts From 2025 ASCO GU

February 12th 2025

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.

Dr Jabbour on Bleximenib Monotherapy in KMT2A+ or NPM1+ R/R Acute Leukemia

February 11th 2025

Elias Jabbour, MD, discusses data for bleximenib in patients with relapsed/refractory acute leukemia harboring KMT2A rearrangements or NPM1 mutations.

Sotorasib Plus Panitumumab Provides Effective Targeted Therapy Option in KRAS G12C+ mCRC

February 11th 2025

Marwan G. Fakih, MD, discusses the FDA approval of sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

The OncFive: Top Oncology Articles for the Week of 2/2

February 8th 2025

Encorafenib combination boosts survival in BRAF V600E+ mCRC, pertuzumab biosimilar BLA is under review for HER2+ breast cancer, and more from OncLive.

Ziftomenib Meets CR/CRh End Point in R/R NPM1+ AML

February 6th 2025

The oral menin inhibitor ziftomenib produced responses in patients with relapsed/refractory NPM1-mutant AML.

CLDN6-Directed Agents Generate Encouraging Early Activity in Solid Tumors

February 5th 2025

Manish R. Patel, MD, and Gottfried E. Konecny, MD, detail findings from studies evaluating CLDN6-directed agents that showed signals of promising efficacy and tolerability.

OncLive’s FDA Approval Report: The Regulatory Rundown for January 2025

February 3rd 2025

Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.

Encorafenib/Cetuximab Plus Chemo Improves Survival in BRAF V600E+ mCRC

February 3rd 2025

Encorafenib plus cetuximab and mFOLFOX6 improved PFS and OS vs chemotherapy in BRAF V600E–mutant metastatic colorectal cancer.

FDA Approves Companion Diagnostic for T-DXd in HER2-Ultralow Metastatic Breast Cancer

February 3rd 2025

The FDA has approved a companion diagnostic for trastuzumab deruxtecan in hormone receptor–positive, HER2-ultralow metastatic breast cancer.

Five Under 5: Top Oncology Videos for the Week of 1/26

February 2nd 2025

The top 5 videos of the week cover insights in gastrointestinal cancers, gynecologic malignancies, and blood cancers.

The OncFive: Top Oncology Articles for the Week of 1/26

February 1st 2025

T-DXd wins FDA approval in HER2-low and -ultralow breast cancer, 177 Lutetium edotreotide boosts PFS in GEP-NETS, and more from OncLive this week.

A Close Look at Clinical Trials in Oncology and Beyond: State of Affairs and Industry Progress

January 30th 2025

In this episode, experts discuss progress in cancer clinical trials and the challenges posed by the increasing complexity of therapies and protocols.

Dr Kaddoura on Challenges Integrating Whole Genome Sequencing Into Clinical Practice in Myeloma

January 30th 2025

Marcella Ali Kaddoura, MD, discusses challenges in integrating whole genome sequencing into routine clinical practice for myeloma.

Encorafenib/Cetuximab Plus Chemo Drives ORR Improvement in BRAF V600E+ mCRC

January 25th 2025

Encorafenib plus cetuximab and mFOLFOX6 improved responses in BRAF V600E–mutated metastatic colorectal cancer.

RAS(ON) Inhibitor Zoldonrasib Is Safe, Shows Early Activity Signals in KRAS G12D–Mutated PDAC

January 24th 2025

Zoldonrasib was well tolerated and associated with manageable AEs and preliminary antitumor activity in patients with KRAS G12D–mutated PDAC.

Unique Questions Associated With the Increasing Prominence of Precision/Genomic Medicine in Routine Cancer Care

January 23rd 2025

Maurie Markman, MD, delves into questions regarding precision medicine and genetic testing in cancer.

The OncFive: Top Oncology Articles for the Week of 1/12

January 18th 2025

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.

FDA Approves Sotorasib Plus Panitumumab for KRAS G12C–Mutated Colorectal Cancer

January 16th 2025

The FDA approved sotorasib plus panitumumab for adult select patients with KRAS G12C–mutated metastatic colorectal cancer.

Savolitinib Earns Full Approval in China for Locally Advanced/Metastatic MET Exon 14+ NSCLC

January 14th 2025

Savolitinib has received full NMPA approval for locally advanced/metastatic non–small cell lung cancer with MET exon 14 skipping alterations.

Neoadjuvant Niraparib Plus Dostarlimab Data Support Development of Non-Chemo Approaches in BRCA+, ER+ Breast Cancer

January 13th 2025

Erica L. Mayer, MD, MPH, responses with preoperative niraparib plus dostarlimab in patients with BRCA-mutant, ER-positive, HER2-negative breast cancer.